Southpoint Capital Advisors LP - AIMMUNE THERAPEUTICS INC ownership

AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 129 filers reported holding AIMMUNE THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.77 and the average weighting 0.9%.

Quarter-by-quarter ownership
Southpoint Capital Advisors LP ownership history of AIMMUNE THERAPEUTICS INC
ValueSharesWeighting
Q2 2020$5,013,000
-72.0%
300,000
-62.5%
0.12%
-83.9%
Q1 2019$17,880,000
-6.6%
800,0000.0%0.76%
-17.9%
Q4 2018$19,136,000800,0000.92%
Other shareholders
AIMMUNE THERAPEUTICS INC shareholders Q2 2019
NameSharesValueWeighting ↓
Foresite Capital Management II, LLC 3,300,797$90,046,00033.32%
Aisling Capital LLC 1,990,000$54,287,00011.73%
Foresite Capital Management III, LLC 801,240$21,858,0004.82%
PACIFIC VIEW ASSET MANAGEMENT, LLC 189,857$5,181,0004.12%
AlpInvest Partners B.V. 38,943$1,062,0002.27%
Eventide Asset Management 1,739,000$47,440,0001.74%
Palo Alto Investors LP 1,381,759$37,694,0001.52%
Sofinnova Investments, Inc. 222,295$6,064,0000.54%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 553,000$15,086,0000.54%
EMERALD ADVISERS, LLC 486,666$13,276,0000.49%
View complete list of AIMMUNE THERAPEUTICS INC shareholders